PDF
Word
This version of the form is not currently in use and is provided for reference only. Download this version of
Form HLTH5469
for the current year.
Form HLTH5469 Special Authority Request - Dalteparin or Tinzaparin for Treatment of Venous Thromboembolism in Cancer Patients - British Columbia, Canada
Form HLTH5469 Special Authority Request - Dalteparin or Tinzaparin for Treatment of Venous Thromboembolism in Cancer Patients in British Columbia, Canada is used to request special authorization for the use of Dalteparin or Tinzaparin for the treatment of venous thromboembolism (blood clots) in cancer patients.
The Form HLTH5469 Special Authority Request is typically filed by healthcare providers or physicians in British Columbia, Canada.
FAQ
Q: What is the HLTH5469 Special Authority Request?
A: The HLTH5469 Special Authority Request is a form used in British Columbia, Canada to request special authority for the use of Dalteparin or Tinzaparin for the treatment of Venous Thromboembolism (VTE) in cancer patients.
Q: What is special authority?
A: Special authority is a process in British Columbia, Canada that allows for the coverage of certain medications or treatments that are not typically covered by the provincial drug program.
Q: What are Dalteparin and Tinzaparin?
A: Dalteparin and Tinzaparin are medications used to prevent and treat blood clots, specifically Venous Thromboembolism (VTE), in cancer patients.
Q: Who is eligible for special authority for Dalteparin or Tinzaparin?
A: Patients in British Columbia, Canada who have cancer and require treatment for Venous Thromboembolism (VTE) may be eligible for special authority for Dalteparin or Tinzaparin.
Q: What is Venous Thromboembolism (VTE)?
A: Venous Thromboembolism (VTE) refers to the formation of blood clots in the veins, usually in the legs or lungs. It is a serious condition that can be life-threatening.
